

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS


IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

5



15




20


5. A pharmaceutical conjugate of claim 1 wherein the efficacy enhancing component is a memantine.

6. A pharmaceutical conjugate of claim 1 wherein the
5 linker is selected from the group consisting of:


10016350-2401
TOPIC 0531001




Linker B




Linker C




Linker D



Linker E



Linker F



Linker G



Linker H

10016850-121101

wherein R12 is an H or a C1-C10 hydrocarbon, m = 0 to
10 10, and n = 0 to 10.

7. A pharmaceutical conjugate of claim 1 wherein the
therapeutic component is selected from the group
consisting of NMDA antagonists, antibacterials,
antihistamines, decongestants, antiinflammatories,
5 antiparasitics, miotics, anticholinergics, adrenergics,
antivirals, local anesthetics, antifungals,
amoebicidals, trichomonocidals, analgesics, mydriatics,
antiglaucoma drugs, carbonic anhydrase inhibitors,
ophthalmic diagnostic agents, ophthalmic agents used as
10 adjuvants in surgery, chelating agents, antineoplastics,
antihypertensives, muscle relaxants, diagnostics,
tyrosine kinase inhibitors and neuroprotectants.

8. A pharmaceutical conjugate of claim 1 wherein the
therapeutic component is selected from the group
consisting of quinoxaline, (2-imidozolin-2-ylamino)
quinoxaline, 5-bromo-6-(2-imidozolin-2-ylamino)
5 quinoxaline, derivatives thereof and mixtures thereof.

9. A pharmaceutical conjugate of claim 1 comprising a
therapeutic component and a memantine, a linker joins
the therapeutic component and the memantine.

10. A pharmaceutical conjugate of claim 1 comprising a
timolol and a memantine, a linker joins the timolol and
the memantine.

11. A pharmaceutical conjugate of claim 1 comprising a
5-bromo-6-(2-imidozolin-2-ylamino) quinoxaline and a
memantine, a linker joins the 5-bromo-6-(2-imidozolin-2-
ylamino) quinoxaline and the memantine.

12. A pharmaceutical conjugate of claim 1 wherein the
therapeutic component and the efficacy enhancing
component disassociate under physiological conditions.

1001650-21401

13. A pharmaceutical conjugate of claim 1 being administered topically.


14. A pharmaceutical conjugate of claim 1 wherein the aqueous solubility, the partition coefficient and/or the affinity for melanin is higher than a compound comprising the same therapeutic component which is not joined to an efficacy enhancing component.

15. A pharmaceutical conjugate of claim 1 being a salt.

16. A pharmaceutical conjugate comprising a therapeutic component and an efficacy enhancing component, the efficacy enhancing component has the general formula A:


5

10




wherein X is


15




20 R1, R2, R3, R4, R5, R6, R7, R8, R9, R10 and R11 are independently an H, a C1-C10 hydrocarbon, or a linker; the linker is selected from the group consisting of:




Linker B




Linker C




Linker D



Linker E



Linker F



Linker G




Linker H


1009660-1-101

wherein R12 is an H or a C1-C10 hydrocarbon, m = 0 to
25 10, and n = 0 to 10.

17. A method for treating an ophthalmic condition, the
method comprising the step of administering a
pharmaceutical conjugate comprising a therapeutic
component and an efficacy enhancing component, the
5 efficacy enhancing component has the general formula I:



wherein X is an H or a



R1, R2, R3, R4, R5, R6, R7, R8, R9, R10 and R11 are
independently an H, a C1-C10 hydrocarbon, or a linker.

35


18. A method of claim 17 wherein R1 and R2 are H, and R3 is a linker.

19. A method of claim 17 wherein the efficacy enhancing component is a memantine.


20. A method of claim 17 wherein the linker is selected from the group consisting of:

10016850-121401


5




Linker B




Linker C




Linker D




Linker E



Linker F



Linker G



Linker H

1005550-2100

wherein R12 is an H or a C1-C10 hydrocarbon, m = 0 to 10, and n = 0 to 10.

21. A method of claim 17 wherein the therapeutic component is selected from the group consisting of NMDA antagonists, antibacterials, antihistamines, decongestants, antiinflammatories, antiparasitics, 5 miotics, anticholinergics, adrenergics, antivirals, local anesthetics, antifungals, amoebicidals, trichomonocidals, analgesics, mydriatics, antiglaucoma drugs, carbonic anhydrase inhibitors, ophthalmic diagnostic agents, ophthalmic agents used as adjuvants 10 in surgery, chelating agents, antineoplastics, antihypertensives, muscle relaxants, diagnostics, tyrosine kinase inhibitors and neuroprotectants.

22. The method of claim 17 wherein the route of administration is topical.

23. The method of claim 17 wherein the route of administration is oral, rectal, sublingual, nasal, and/or intravenous.

10016550-121401

Amanhidin